Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health"), today announced its exclusive ONE by ONE and Biotrue ® Eye Care Recycling programs have recycled a total of 48,235,850 million units, or 290,145 pounds, of used contact lenses, eye care and lens care materials, which is the equivalent of the weight of approximately 31 elephants. 1 Both programs are made possible through a collaboration with TerraCycle ® a world leader in the collection and repurposing of hard-to-recycle post-consumer waste.

"For six years we have collaborated with TerraCycle to offer contact lens wearers a free and convenient way to recycle their used contact lenses and packaging materials. Building upon the success of the ONE by ONE program, we created the Biotrue ® Eye Care Recycling program in 2021, which allows consumers to also recycle their used eye care and lens care materials, such as lens cases and lens solution bottle caps," said Amy Butler , global vice president, Environment, Health, Safety and Sustainability, Bausch Health. "Together, these programs are helping us keep recyclable plastic and aluminum eye health materials out of landfills and oceans so we can help preserve our environment for future generations."

Bausch + Lomb developed these programs in conjunction with TerraCycle because used contact lenses, eye care and lens care materials don't typically end up getting processed in standard recycling facilities. These materials are traditionally sent to landfills, because recycling facilities only accept certain types of plastic and filter out small-sized materials.

"Through their two first-of-their-kind recycling programs, Bausch + Lomb is providing consumers with a sustainable way to recycle eye health materials," said Tom Szaky, founder and CEO, TerraCycle. "As a result of our efforts with Bausch + Lomb, we are making sure these typically forgotten waste streams are supported and given new life as various recycled products, rather than ending up in the environment."

The ONE by ONE Recycling program has collected more than 48 million units of used contact lenses, top foils and blister packs since its launch in 2016. Additionally, since launching in April 2021 , the Biotrue ® Eye Care Recycling program, which is the first and only eye care recycling program in the United States , has collected more than 153,222 eye drop single dose units, lens cases and lens solution caps, as well as Biotrue ® Hydration Boost lubricant eye drops multi-dose bottles. (Lens solution bottles can be recycled through standard recycling in accordance with local recycling guidelines).

In addition to the United States , Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts. More about the Bausch + Lomb ONE by ONE Recycling program can be found here , and more about the Biotrue ® Eye Care Recycling program can be found here .

About the Biotrue ® Eye Care Recycling Program
The Bausch + Lomb Biotrue ® Eye Care Recycling program is the first and only eye care recycling program in the United States . This program allows consumers who participate to properly recycle all brands of their eye drop single dose units, lens cases and lens solution caps*, as well as Biotrue ® Hydration Boost lubricant eye drops multi-dose bottles. Once consumers collect these items, they can be mailed to TerraCycle using a pre-paid shipping label. When the waste arrives at the TerraCycle facility, it is cleaned and melted into hard plastic pellets that can be used to make new recycled products.

About the ONE by ONE Recycling Program
The Bausch + Lomb ONE by ONE Recycling program is the first and only sponsored contact lens recycling program in the United States . This award-winning program collects used contact lenses, top foil and opened plastic blister packs from any brand and is available to contact lens wearers and eye care professionals. More than 7,000 eye care practices are registered as official recycling centers of the program. To participate, contact lens wearers can bring their used contact lenses and packaging to one of these practices, which collects the used lens materials in a custom recycling bin provided by Bausch + Lomb. Once the bin is filled, the optometry practice ships the materials to TerraCycle for proper recycling using a Bausch + Lomb pre-paid shipping label.

About TerraCycle
TerraCycle is an innovative waste management company with a mission to eliminate the idea of waste. Operating nationally across 21 countries, TerraCycle partners with leading consumer product companies, retailers and cities to recycle products and packages, from dirty diapers to cigarette butts, that would otherwise end up being landfilled or incinerated. In addition, TerraCycle works with leading consumer product companies to integrate hard to recycle waste streams, such as ocean plastic, into their products and packaging. Its new division, Loop, is the first shopping system that gives consumers a way to shop for their favorite brands in durable, reusable packaging. TerraCycle has won over 200 awards for sustainability and has donated over $44 million to schools and charities since its founding more than 15 years ago and was named #10 in Fortune magazine's list of 52 companies Changing the World. To learn more about TerraCycle or get involved in its recycling programs, please visit www.terracycle.com .

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies, Inc., is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey . For more information, visit www.bausch.com and connect with us on Twitter , LinkedIn , Facebook and Instagram .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") is a global company whose mission is to improve people's lives with our health care products. Bausch Health develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. Bausch Health is delivering on its commitments as it builds an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

*Lens solution bottles can be recycled through standard recycling in accordance with local recycling guidelines.

References

  1. Elephants for Africa . Retrieved from: https://www.elephantsforafrica.org/elephant-facts/ . Accessed April 5, 2022 .

TerraCycle is a trademark of TerraCycle Inc.
  Biotrue is a trademark of Bausch & Lomb Incorporated or its affiliates.
  ©   2022 Bausch & Lomb Incorporated   or its affiliates.
  OBO.0008.USA.22

Media Contact:

Bausch Health Investor Contact:


Sue Kauffman

Arthur Shannon


sue.kauffman@terracycle.com

arthur.shannon@bauschhealth.com


(609) 393-4252 x3708

(514) 865-3855



(877) 281-6642 (toll free)






Bausch Health Media Contact:



Lainie Keller



lainie.keller@bauschhealth.com



(908) 927-1198


Bausch + Lomb (PRNewsfoto/Bausch + Lomb)

Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

TerraCycle

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch--lomb-reports-more-than-48-million-units-of-contact-lens-eye-care-and-lens-care-materials-recycled-through-one-by-one-and-biotrue-eye-care-recycling-programs-301529748.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

BHC:CA,BHC
The Conversation (0)
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C

"We are pleased to present late-breaking data on Amiselimod, our investigational, oral, sphingosine 1-phosphate (S1P) receptor modulator as a potential treatment for the induction of remission in UC," said Tage Ramakrishna, M.D., Chief Medical Officer and President of Research & Development, Bausch Health. "The abstract underscores our steadfast commitment to developing new and innovative therapies for patients with UC."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, Inc

With respect to the April 11, 2024, decision of the US Court of Appeals for the Federal Circuit, both Bausch Health and Norwich have filed petitions for panel rehearing or rehearing en banc. The Company anticipates a decision on whether a rehearing will be granted within the next three months.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Star Jones , award winning television personality & women's heart health advocate,   helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S. many women are still unaware of the risk and the importance of heart health.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×